Abstract 2326
Background
Large tumor suppressor kinase 2 (LATS2) is one of the core components in the Hippo signaling pathway, and it functions as a tumor suppressor associated with regulating tumor cell proliferation and apoptosis. Dysregulated LATS2 expression has been reported in various human cancers. The purpose of this study is to explore LATS2 expression and its clinicopathological significance in non-small cell lung cancer (NSCLC) and its subtypes.
Methods
We examined LATS2 protein expression by immunohistochemistry in 184 resected NSCLC specimens on tissue microarray. We also reviewed the clinical data and performed a clinicopathological analysis.
Results
Of 184 lung cancer specimens, 40 (21.7%) showed low LATS2 expression. Low LATS2 expression was significantly correlated with disease recurrence (p = 0.047) and low LATS2 expression had a tendency of poor prognostic clinicopathological features including large tumor size, the presence of vascular and lymphatic invasion and distant metastasis. The low LATS2 expression group showed a statistically poorer overall survival (OS) (p = 0.004) and disease-free survival (DFS) (p = 0.014) than did the high expression group in Kaplan-Meier analysis with log-rank test. In multivariate analysis with the Cox proportional hazards model, downregulated LATS2 expression in NSCLC was an independent prognostic factor of poor OS and DFS. Furthermore, we evaluated the prognostic significance of LATS2 expression in two major subtypes of NSCLC, squamous cell carcinoma and adenocarcinoma, using the Kaplan-Meier curves with log-rank test. In both squamous cell carcinoma and adenocarcinoma, low LATS2 expression group showed worse prognosis than high LATS2 expression group (OS (p = 0.144), DFS (p = 0.022) in squamous cell carcinoma and OS (p = 0.045), DFS (p = 0.271) in adenocarcinoma).
Conclusions
In conclusion, we demonstrated that downregulated LATS2 expression may predict aggressive biologic behavior and a worse prognosis in NSCLC and we also suggested the possibility of LATS2 as a therapeutic target in both squamous cell carcinoma and adenocarcinoma of the lung.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Soonchunhyang University Research Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4079 - Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Presenter: Gabriela Kramer-marek
Session: Poster Display session 1
Resources:
Abstract
4364 - Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma
Presenter: Gema Bruixola
Session: Poster Display session 1
Resources:
Abstract
2327 - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas
Presenter: Itai Moshe
Session: Poster Display session 1
Resources:
Abstract
3154 - Preclinical Study of Novel Tetracyclic Small Molecule, CC12, for Brain Cancer
Presenter: Liyun Fann
Session: Poster Display session 1
Resources:
Abstract
5759 - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma
Presenter: Inge Compter
Session: Poster Display session 1
Resources:
Abstract
1382 - A Phase II Clinical Trial Evaluating the Efficacy and Safety of Apatinib Combined with dose-dense Temozolomide in Recurrent Glioblastoma
Presenter: Yong Wang
Session: Poster Display session 1
Resources:
Abstract
4407 - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma
Presenter: Shwetal Mehta
Session: Poster Display session 1
Resources:
Abstract
1469 - Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): an observational study
Presenter: Mario Caccese
Session: Poster Display session 1
Resources:
Abstract
4217 - Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): a single-center experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
5107 - Tolerability of PCV in Low Grade Glioma: a Real World Experience
Presenter: Razia Aslam
Session: Poster Display session 1
Resources:
Abstract